Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 225
Filtrar
1.
Anemia ; 2012: 105349, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22830000

RESUMEN

High HbF levels and F cells are correlated with reduced morbidity and mortality in sickle cell disease (SCD). This paper was designed to determine the HbF and F cells levels in Congolese sickle cell anemia (SCA) patients in order to determine their impact on the expression of SCD. Population and Method. HbF levels were measured in 89 SCA patients (mean age 11.4 yrs) using a standard HPLC method. F cell quantitation was done in a second group of SCA patients (n = 42, mean age 8.9 yrs) and compared with a control group (n = 47, mean age 5 yrs). F cells were quantified by a cytofluorometric system (MoAb-HbF-FITC; cut off at 0.5%). Results. The mean value of HbF was 7.2% ± 5.0 with heterogeneous distribution, most patients (76%) having HbF < 8%. Mean values of F-cells in SCA patients and control group were 5.4% ± 7.6 (median: 2.19%; range 0,0-30,3%) and 0.5% ± 1.6 (median 0.0, range 0-5.18), respectively. SCA patients with F cells >4.5% developed less painful crisis and had higher percentage of reticulocytes. Conclusion. Congolese SCA patients displayed low levels of HbF and F-cells that contribute to the severity of SCD.

2.
Med Trop (Mars) ; 70(5-6): 449-53, 2010 Dec.
Artículo en Francés | MEDLINE | ID: mdl-21520645

RESUMEN

Sickle cell disease is a genetic blood disorder caused by a glutamic to valine acid substitution in the beta chain of the hemoglobin protein. It was first reported in the United States where most research has been carried out on subjects of African descent. It is diffused throughout the world. Epidemiological data show that the highest incidence of sickle cell anemia is in sub-Saharan Africa where the severest forms are often fatal in children under the age of 5 years. The clinical course of the disease in Africa is comparable to that described in industrialized countries. The three cardinal symptoms are hemolytic anemia, painful episodes, and susceptibility to infection. Genotype and phenotype variations have been observed from one zone to another in Africa. Greater severity is due to a combination of various factors including constant coexistence with Plasmodium falciparum malaria and omnipresence of pyogenic factors as well as to the unfavorable demographic setting involving endogamy, poor healthcare facilities, and poor socio-economic conditions. A hundred years of research has provided a good understanding of the pathophysiological mechanisms that can sometimes be improved by to primary hydroxyurea therapy. Sickle cell disease remains a major health problem in Africa where patients do not currently benefit from the same treatment as in industrial countries.


Asunto(s)
Anemia de Células Falciformes/epidemiología , África/epidemiología , Anemia de Células Falciformes/diagnóstico , Anemia de Células Falciformes/genética , Infecciones Bacterianas/epidemiología , Humanos , Malaria Falciparum/epidemiología , Infecciones Oportunistas/epidemiología
3.
Tissue Antigens ; 59(5): 417-20, 2002 May.
Artículo en Inglés | MEDLINE | ID: mdl-12144626

RESUMEN

CD1 gene (CD1A to CD1E) products are involved in non-peptide antigen presentation, such as lipids and glycolipids, to T cells. With a similar function to MHC, namely antigen presentation, these genes nevertheless displayed a much lower level of polymorphism as compared to MHC. We report here two additional CD1E variants identified in black African individuals, designated herein CD1E*05 and CD1E*06. While the former differs from the common (wild type) allele sequence by two substitutions at nucleotide positions 217 and 229 of exon 2, the latter only by a single base change at position 91 of exon 3. These substitutions lead to amino acid changes at position 73 and 77 of the alpha1 domain in the former and at position 30 of the alpha2 domain in the latter. Identification of these additional variants suggests that the CD1 locus, especially the CD1E gene, is much more polymorphic than previously assumed.


Asunto(s)
Antígenos CD1/genética , Población Negra/genética , Polimorfismo Genético , África , Secuencia de Aminoácidos , Sustitución de Aminoácidos/genética , Secuencia de Bases , Humanos , Datos de Secuencia Molecular
4.
Hum Genet ; 104(4): 307-14, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10369160

RESUMEN

Short tandem repeats are abundantly present within the genome. They are commonly used as polymorphic markers but their potential functional role is poorly documented. Several of these microsatellites have been described within the beta-globin locus and some could be involved in controlling gene expression. Our purpose was to investigate the extent and significance of the (TG)n(CG)m dinucleotide repeat polymorphisms in the two gamma-globin gene IVS2s. Two groups of subjects were studied: a group of 63 beta-thalassaemic patients presenting either with a severe Cooley's anaemia (n=50) or with thalassaemia intermedia (TI, n=13), and a control group of 60 unrelated healthy individuals. A high heterogeneity of the polymorphic repeats was demonstrated, extending the range of the published alleles from 13 to 22 and allowing a first attempt at making a phenotype/genotype correlation. One specific allele, (TG)13 in the Agamma-gene, was highly enriched in the TI patients (46.1% vs 2.9% of the Cooley's anaemia cases, P < 0.0002, and 23.3% in the normal controls, P < 0.008) and preferentially observed in TI patients with a high haemoglobin F (Hb F). Transient transfection assays in K562 cells, with the growth hormone gene as a reporter, showed a positive regulatory action mediated by a (TG)13-containing 243 nt IVS2 fragment. Finally, a first set of mobility shift experiments with erythroid (K562 and MEL) and nonerythroid (HeLa) cell lines showed binding of erythroid component(s) in this DNA region and the binding pattern was modified upon induction of MEL cells by DMSO. Thus, our in vivo and in vitro data raise the question of a possible contribution of the gamma-gene IVS2s polymorphic microsatellites to the variable Hb F synthesis in the major haemoglobinopathies: a well known, puzzling and still unanswered question.


Asunto(s)
Repeticiones de Dinucleótido , Hemoglobina Fetal/genética , Variación Genética , Globinas/genética , Polimorfismo Genético , Talasemia beta/genética , Línea Celular , Genotipo , Globinas/biosíntesis , Células HeLa , Hormona de Crecimiento Humana/biosíntesis , Hormona de Crecimiento Humana/genética , Humanos , Células K562 , Fenotipo , Reacción en Cadena de la Polimerasa , Proteínas Recombinantes/biosíntesis , Valores de Referencia , Transfección , beta-Galactosidasa/genética
5.
Curr Opin Hematol ; 6(2): 115-20, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10088642

RESUMEN

Hydroxyurea is the first drug that, under well-organized, large-scale trials in adults, has shown a beneficial effect on the clinical course of sickle cell disease. Several small-scale trials have been conducted in children, but they used different therapeutic schedules, and only one was a single-blind crossover trial. Still, children are clearly good responders to the treatment because a rapid clinical improvement was observed, with decreased frequencies of vaso-occlusive crises, acute chest syndromes, and transfusion requirements. Despite large interindividual variations, virtually all the children studied increased their fetal hemoglobin, mean corpuscular volume, and total hemoglobin. Follow-up varied from 6 months to 59 months. More than in adults, the fetal hemoglobin increase was sustained, and few side effects were observed. Large-scale, placebo-controlled studies seem no longer needed. Guidelines concerning patient selection, dosing schedules, and monitoring protocols as well as exhaustive registries for the detection of long-term side effects are necessary.


Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Antidrepanocíticos/uso terapéutico , Hidroxiurea/uso terapéutico , Adolescente , Adulto , Antidrepanocíticos/efectos adversos , Niño , Preescolar , Método Doble Ciego , Humanos , Hidroxiurea/efectos adversos , Estudios Longitudinales , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento
6.
Pathol Biol (Paris) ; 47(1): 7-12, 1999 Jan.
Artículo en Francés | MEDLINE | ID: mdl-10081773

RESUMEN

The beta S mutation responsible for sickle cell disease (SCD) was identified in 1949. This mutation always consists in a T for A substitution at codon 6 of the beta-globin chain. Deoxygenated HbS becomes polymerized, producing erythrocyte shape changes and vasoocclusion. Still unexplained is the wide variability in clinical expression of SCD, whose spectrum ranges from severely incapacitating forms to virtually silent forms. Recent research has focused on genetic or environmental factors that may interfere with one or more steps of the basic pathophysiologic mechanisms. These factors can be roughly classified in three groups: i) factors that modify HbS levels within erythrocytes, thereby impacting the propensity of HbS for polymerization; ii) other normal or abnormal hemoglobins present in the erythrocyte that may modify side contacts of the hemoglobin molecule within the polymer, thus either stopping or enhancing polymerization; iii) molecules other than hemoglobin expressed at the surface of the SCD reticulocytes that may adhere to the vascular endothelium, thus slowing flow in the microcirculation and delaying HbS reoxygenation. Whatever the starting point, the same vicious circle is set in motion. These mechanisms have generally been studied separately, in vitro, under artificial conditions. An important goal is to understand how they interact in vivo in a given patient.


Asunto(s)
Anemia de Células Falciformes/fisiopatología , Anemia de Células Falciformes/genética , Biopolímeros , Eritrocitos Anormales/patología , Globinas/genética , Hemoglobinas/fisiología , Humanos , Mutación
9.
Gene ; 213(1-2): 169-77, 1998 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-9630612

RESUMEN

We report the allelic sequence polymorphism associated with seven beta-thalassaemia mutations. Thirty-two DNAs originating from Algeria and 12 DNAs from Sardinia and Sicily were investigated. Their analysis revealed an association with a unique haplotype for three beta-thalassaemia mutations (-29, IVS-I-2 and IVS-I-1). It seems clear that these mutations have a unicentric origin. The presence of the -29 mutation could be explained by migration and founding effect. However, the local origin of IVS-I-2 seems clear. The four other mutations, FS6, IVS-I-6, IVS-I-110 and stop39 were found to be associated with at least two different sequence haplotypes. The likelihood of so many recurrent nucleotide dimorphisms in different lineages as a consequence of random mutation is very low; it is supported neither by the analysis of equivalent regions in other primates, nor by the presence of highly mutable sites such as CpG dinucleotides. The fact that these mutations are found exclusively in the Mediterranean area is not in favour of a recurrent origin of the mutation. The diversity is far more important for the preponderant thalassaemia mutations of the Mediterranean area and is higher in the 5' part of the beta-globin gene. Hence, the IVS-I-110, the preponderant beta-thalassaemia in the Eastern Mediterranean, probably emerged in the extension of the fertile crescent. For the stop39, all the data support the hypothesis of a West-Mediterranean origin. The diversity of haplotypes would then be generated by recombination events (crossing-over or gene conversions) between the original beta-thalassaemia chromosome and the other chomosomal structures present in the normal population.


Asunto(s)
Frecuencia de los Genes , Globinas/genética , Haplotipos/genética , Talasemia beta/genética , Argelia/epidemiología , Alelos , ADN/genética , Análisis Mutacional de ADN , Conversión Génica , Variación Genética , Humanos , Italia/epidemiología , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Sicilia/epidemiología , Talasemia beta/etnología
10.
Am J Hematol ; 56(4): 239-43, 1997 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9395185

RESUMEN

Expression of fetal hemoglobin (Hb F) is under polygenic control involving determinants both linked and unlinked to the beta-globin gene cluster on chromosome 11. Variations in the DNase I-hypersensitive site 2 of the locus control region (LCR-HS2) and a C --> T change at position -158 from the Ggamma-gene (detected as an XmnI polymorphism) correlate with the high level of Hb F expression in patients with sickle-cell anemia and beta-thalassemia. Interpretation of data under these conditions of anemic stress is difficult because the preferential survival of Hb F-containing erythrocytes (F-cells) may not reflect the true status of Hb F expression. We investigated the relationship between these markers and Hb F expression in terms of F-cell levels in 48 unrelated non-anemic AS heterozygotes from Sicily. The betaS-chromosome of all these individuals was of the Benin haplotype and they differed only by their betaA chromosomes. We demonstrate that F-cell expression is more strongly associated with LCR-HS2 polymorphism than with XmnI polymorphism. The observed association between XmnI polymorphism and Hb F expression is very likely to be due to linkage disequilibrium with LCR-HS2 sequences.


Asunto(s)
Anemia de Células Falciformes/genética , Hemoglobina Fetal/genética , Globinas/genética , Familia de Multigenes , Polimorfismo Genético , Adulto , Anciano , Anemia de Células Falciformes/metabolismo , Anemia de Células Falciformes/patología , ADN/análisis , Recuento de Eritrocitos , Femenino , Hemoglobina Fetal/biosíntesis , Regulación de la Expresión Génica , Marcadores Genéticos , Haplotipos/genética , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Metiltransferasa de ADN de Sitio Específico (Adenina Especifica)/genética
11.
J Pediatr Hematol Oncol ; 19(4): 313-8, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9256830

RESUMEN

PURPOSE: To observe the safety and efficacy of hydroxyurea (HU), a drug that stimulates fetal hemoglobin (Hb F) production, in previously severely ill children with sickle cell disease. PATIENTS AND METHODS: HU was given in an uncontrolled study to 35 children with sickle cell disease, aged from 3 to 20 years, suffering from frequent painful crises. Mean duration of treatment was 32 months (range: 12-59 months). RESULTS: HU induced an increase in Hb F levels in all children out one; this increase was maximal after 9 months of treatment, was largely sustained thereafter, and was related to HU dose and inversely to patients' age. We also noted an apparent reduction in crisis, which occurred principally after 3 months of therapy and did not seem strictly correlated with the rise in Hb F level. No serious hematopoietic complication was observed. Growth curves and sexual development were not modified. CONCLUSION: Our data support the efficacy of HU in reducing painful events in children with sickle cell disease. Short- and middle-term tolerances are good. Thus, we think that HU can be given to children affected by frequent and severe painful crises. We recommend, however, very cautious use of this drug, because its long-term effects in children are still unknown.


Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Antidrepanocíticos/uso terapéutico , Hidroxiurea/uso terapéutico , Adolescente , Adulto , Anemia de Células Falciformes/sangre , Antidrepanocíticos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas , Niño , Preescolar , Femenino , Hemoglobina Fetal/metabolismo , Estudios de Seguimiento , Crecimiento/efectos de los fármacos , Cabello/efectos de los fármacos , Hemoglobinas/metabolismo , Humanos , Hidroxiurea/efectos adversos , Hiperpigmentación/inducido químicamente , Enfermedades Renales/inducido químicamente , Masculino , Enfermedades de la Uña/inducido químicamente , Pubertad/efectos de los fármacos
12.
Hum Genet ; 99(3): 381-6, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9050927

RESUMEN

To evaluate the allelic frequency and genetic diversity of alpha-thalassemia defects in Sicily, both epidemiological and patient-oriented studies were carried out. For the epidemiological study, phenotypic data were collected on more than 1000 Sicilian individuals. Among them, 427 were explored at the molecular level for nine alpha-thalassemic variants known to be common in the Mediterranean region. Our data reveal an allele frequency of 4.1% for alpha(+)-thalassemia matching that of beta-thalassemia in this region. The presence of alpha0-thalassemia (--MEDI and --CAL) was observed only in the group of referred patients. Newly acquired nucleotide sequence data on the deletional breakpoint of --CAL allowed us to design a simple PCR-based procedure for exploring this allele. The data also provide additional information concerning the genetic mechanisms involved in such large deletions.


Asunto(s)
Mutación , Talasemia alfa/genética , Adolescente , Secuencia de Bases , Niño , Preescolar , ADN , Análisis Mutacional de ADN , Eliminación de Gen , Frecuencia de los Genes , Genotipo , Humanos , Datos de Secuencia Molecular , Fenotipo , Sicilia/epidemiología , Talasemia alfa/epidemiología
13.
Eur J Hum Genet ; 5(6): 390-6, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9450184

RESUMEN

We have studied haemoglobin (Hb) variants and blood groups (ABO, RH, and Kell) in 598 children from the Berber population of the Mzab. Hb D-Ouled Rabah, considered as a private marker of the Kel Kummer Tuaregs, and Hb C were found at the same gene frequency (0.015). Haplotype analysis suggests a single origin to the Hb D mutation. Genetic distances calculated from the blood group data cluster Mozabites and Tuaregs with the other Berber-speaking groups, Arabic-speaking populations being more distant. But, we found no specific relationship between Mozabites and Kel Kummers. Tuaregs in general exhibit features that tend to differentiate them from other Berber-speaking groups. Hb D-Ouled Rabah may be specific of Berber-speaking populations.


Asunto(s)
Antígenos de Grupos Sanguíneos/genética , Etnicidad/genética , Hemoglobinas/genética , Argelia , Análisis Mutacional de ADN , Frecuencia de los Genes , Marcadores Genéticos/genética , Haplotipos , Hemoglobina C/genética , Hemoglobinas/análisis , Hemoglobinas Anormales/genética , Humanos , Polimorfismo Genético/genética
14.
Hemoglobin ; 20(2): 85-101, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8811312

RESUMEN

The purpose of this review is to give a general up-date of the most recent developments concerning polymorphisms within the beta-globin gene cluster. The first polymorphisms to be identified were mostly restriction fragment length polymorphisms. They were important markers both for their use as diagnostic tools and for anthropological investigations. Although they have been associated with specific patterns of globin gene expression in the hemoglobinopathies, none have been demonstrated to have any intrinsic functional significance. More recently, additional single nucleotide variations and microsatellite-like polymorphic simple sequence repeats have been identified which are frequently located in trans-acting protein binding segments and hence might affect regulatory processes.


Asunto(s)
Anemia de Células Falciformes/genética , Globinas/genética , Polimorfismo de Longitud del Fragmento de Restricción , Humanos , Familia de Multigenes , Mapeo Restrictivo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...